BIOLIDICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.012 SGD | +9.09% |
|
+20.00% | -14.29% |
| May. 20 | Bioldics' Financial Controller Steps Down | MT |
| May. 17 | Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 2.54M 1.88M | Sales 2023 | 1.36M 1.01M | Capitalization | 9.21M 6.83M |
|---|---|---|---|---|---|
| Net income 2022 | -9M -6.68M | Net income 2023 | -2M -1.48M | EV / Sales 2022 | 3.87 x |
| Net cash position 2022 | 2.02M 1.5M | Net Debt 2023 | 1.84M 1.37M | EV / Sales 2023 | 8.12 x |
| P/E ratio 2022 |
-0.72
x | P/E ratio 2023 |
-3.33
x | Employees | 15 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +9.09% | ||
| 1 week | +20.00% | ||
| 6 months | -7.69% | ||
| Current year | -14.29% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.01
1 year
0.010.02
3 years
0.010.35
5 years
0.010.89
10 years
0.010.89
| Managers | Title | Age | Since |
|---|---|---|---|
Tang Yih Song
CEO | Chief Executive Officer | 59 | 21-08-31 |
Hafiza Alwi Nor
SEC | Corporate Secretary | - | - |
Yeung Sau Siu
AUD | Comptroller/Controller/Auditor | 50 | 22-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tang Yih Song
CEO | Chief Executive Officer | 59 | 21-08-31 |
Li-Ling Ch'ng
BRD | Director/Board Member | 53 | 23-03-30 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | Nov. 26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.012 | +9.09% | 101,000 |
| 24-05-20 | 0.011 | 0.00% | 350,100 |
| 24-05-17 | 0.011 | 0.00% | 491,000 |
| 24-05-16 | 0.011 | -8.33% | 1,053,200 |
| 24-05-15 | 0.012 | +20.00% | 4,463,100 |
Delayed Quote Singapore S.E., May 21, 2024 at 04:56 am EDT
More quotes
Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device, which separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singaporeâs Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapore.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.29% | 6.08M | |
| +11.18% | 227B | |
| +15.22% | 198B | |
| +19.19% | 142B | |
| +30.89% | 111B | |
| +1.56% | 64.16B | |
| +18.48% | 54.1B | |
| +5.12% | 51.41B | |
| +10.53% | 45.32B | |
| +5.98% | 37.32B |
- Stock Market
- Equities
- 8YY Stock